Nyrada Clears Pilot Study Hurdle and Eyes Larger Heart Protection Trial in 2026
Nyrada completes Xolatryp cardioprotection pilot study, paving the way for larger cardiomyopathy programme
Nyrada Inc. (ASX: NYR), a clinical-stage biotechnology company focused on Transient Receptor Potential Canonical (TRPC) ion channel inhibitors, has successfully completed a pilot preclinical cardioprotection study evaluating its lead drug candidate Xolatryp in combination with doxorubicin. Preliminary biomarker data showed numerically lower mean cardiac troponin I (cTnI) in both Xolatryp treatment groups compared with the doxorubicin plus vehicle control group. The study confirmed the feasibility and tolerability of the subcutaneous dosing regimen and will directly inform dose selection for Nyrada’s larger, adequately powered cardiomyopathy study, with results expected in Q3 CY2026.
When big ASX news breaks, our subscribers know first
Understanding the problem Xolatryp is designed to solve
Anthracycline drugs, including doxorubicin, are widely used in oncology, but their clinical application can be limited by cumulative, dose-dependent cardiac injury. There is a recognised gap for therapies that may reduce this cardiotoxicity without compromising anti-tumour activity. This is the challenge Nyrada is targeting with Xolatryp.
Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca²⁺ entry, a process implicated in multiple disease pathologies including cardiac injury. In plain terms, these channels act as gateways that, when overactivated, allow too much calcium into heart cells, contributing to tissue damage. Nyrada is investigating whether Xolatryp can serve as a cardioprotective adjunct alongside anthracycline chemotherapy, a distinct and commercially relevant use case separate from its STEMI programme.
What the pilot study found, and what comes next
Study design at a glance
The pilot study was designed to assess feasibility and tolerability, not to demonstrate statistical efficacy. Mice received doxorubicin weekly for two weeks, with Xolatryp administered subcutaneously at two dose levels across three consecutive days.
Key study parameters:
- Doxorubicin dose: 5 mg/kg intravenously, once weekly for two weeks
- Xolatryp doses tested: 12 mg/kg/day and 36 mg/kg/day
- Administration: subcutaneous, four times daily, three consecutive days
- Groups: n = 3 per group
- Key biomarker measured: cardiac troponin I (cTnI)
The pilot was explicitly not designed or powered to demonstrate statistical significance for an efficacy readout.
Key findings
Preliminary biomarker data showed numerically lower mean cTnI levels in both Xolatryp treatment groups relative to the doxorubicin plus vehicle control group. No unexpected safety observations were recorded during the study, and no significant alterations were seen in body weight or liver enzymes across any dose level. These results provide initial evidence supporting further investigation of Xolatryp’s potential cardioprotective activity.
The table below summarises the available outcomes across the three study groups.
| Group | Xolatryp Dose | cTnI Result (vs. control) | Body Weight Change | Safety Observations |
|---|---|---|---|---|
| Doxorubicin + Vehicle (control) | N/A | Reference | No significant change | None noted |
| Doxorubicin + Xolatryp | 12 mg/kg/day | Numerically lower | No significant change | None noted |
| Doxorubicin + Xolatryp | 36 mg/kg/day | Numerically lower | No significant change | None noted |
It is important to note that given the pilot’s limited sample size (n = 3 per group), these findings are early-stage and exploratory in nature.
The road to a larger, powered cardiomyopathy study
The results of the pilot will be used to finalise the design of Nyrada’s larger cardiomyopathy study, which represents the next direct investment catalyst from this programme. The larger study is intended to provide a more statistically meaningful assessment of Xolatryp’s potential.
Key parameters for the larger study include:
- Approximately 12 animals per group (compared with 3 in the pilot)
- A five-week treatment period (compared with two weeks)
- Clinically relevant doxorubicin exposure
- Comprehensive cardiac assessments covering biomarkers, cardiac function, and histopathology
- Results expected in Q3 CY2026
As with the pilot, subcutaneous dosing in the preclinical study serves as a proxy for intravenous dosing in a clinical setting.
The next major ASX story will hit our subscribers first
Where Xolatryp fits in Nyrada’s broader clinical picture
Xolatryp has completed a Phase I clinical trial assessing its safety, tolerability, and pharmacokinetics. A Phase IIa clinical trial is currently underway to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing percutaneous coronary intervention (PCI).
The cardiomyopathy cardioprotection programme represents an additional and distinct application being pursued in parallel, broadening the addressable clinical opportunity for the asset. For investors, Q3 CY2026 is a near-term catalyst to monitor, with the larger study designed to further define the dose-response relationship and evaluate Xolatryp’s potential to mitigate anthracycline-induced cardiac injury. At this stage, the evidence remains early, with further investigation required before any efficacy conclusions can be drawn.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, with in-depth analysis included. Over 20,000 subscribers are already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.